These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38287501)

  • 1. Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.
    Yhim HY; Park Y; Kim JA; Shin HJ; Do YR; Moon JH; Kim MK; Lee WS; Kim DS; Lee MW; Choi YS; Jeong SH; Kim KH; Kim J; Lee CH; Song GY; Yang DH; Kwak JY
    Korean J Intern Med; 2024 May; 39(3):501-512. PubMed ID: 38287501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
    Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
    Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
    Lee HS; Lee J; Jo JC; Jung SH; Lee JJ; Kim D; Lee S; Song K
    Sci Rep; 2021 Nov; 11(1):22907. PubMed ID: 34824362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma.
    Spina M; Balzarotti M; Uziel L; Ferreri AJ; Fratino L; Magagnoli M; Talamini R; Giacalone A; Ravaioli E; Chimienti E; Berretta M; Lleshi A; Santoro A; Tirelli U
    Oncologist; 2012; 17(6):838-46. PubMed ID: 22610154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
    Yagi Y; Kanemasa Y; Sasaki Y; Goto S; Yamamura Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimoyama T
    Ann Hematol; 2023 Jun; 102(6):1485-1500. PubMed ID: 37115298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.
    Ong DM; Ashby M; Grigg A; Gard G; Ng ZY; Huang HE; Chong YS; Cheah CY; Devitt B; Chong G; Loh Z; Mo A; Hawkes EA
    Br J Haematol; 2019 Oct; 187(1):73-81. PubMed ID: 31206608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma.
    Tanaka T; Sakai R; Choi I; Tsukada J; Sasaki H; Naito Y; Kiyomi F; Takamatsu Y; Tamura K
    Sci Rep; 2022 Feb; 12(1):3124. PubMed ID: 35210509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma.
    Miura K; Konishi J; Miyake T; Makita M; Hojo A; Masaki Y; Uno M; Ozaki J; Yoshida C; Niiya D; Kitazume K; Maeda Y; Takizawa J; Sakai R; Yano T; Yamamoto K; Sunami K; Hiramatsu Y; Aoyama K; Tsujimura H; Murakami J; Hatta Y; Kanno M
    Oncologist; 2017 May; 22(5):554-560. PubMed ID: 28408622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
    Jung YH; Woo IS; Han CW
    Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B-Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment.
    Liu H; Zhang CL; Feng R; Li JT; Tian Y; Wang T
    Oncologist; 2018 Jun; 23(6):722-729. PubMed ID: 29317552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comprehensive geriatric assessment can predict the clinical outcomes of elderly patients with diffuse large B cell lymphoma in China].
    Zhang CL; Feng R; Li JT; Tian Y; Wang T; Liu H
    Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):271-276. PubMed ID: 29779319
    [No Abstract]   [Full Text] [Related]  

  • 12. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
    Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
    Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
    Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.
    Isaksen KT; Mastroianni MA; Rinde M; Rusten LS; Barzenje DA; Ramslien LF; Slaaen M; Jerm MB; Smeland EB; Rostoft S; Liestøl K; Brodtkorb M; Holte H
    Blood Adv; 2021 Nov; 5(22):4771-4782. PubMed ID: 34543384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Yamamoto M; Suzuki I; Saitou K; Tsumanuma R; Okuyama S; Kumagai H; Omoto E; Satoh S; Tajima K
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2995-3002. PubMed ID: 32524293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma.
    Sakurai M; Karigane D; Kasahara H; Tanigawa T; Ishida A; Murakami H; Kikuchi M; Kohashi S
    Ann Hematol; 2019 Mar; 98(3):669-678. PubMed ID: 30443764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Individualization in Diffuse Large B-Cell Lymphoma: Is Frailty Enough for Old Adults? An Original Article.
    García-Baztán A; Oteiza-Olaso J; Gonzales-Montejo NJ; Ramón-Espinoza MF; Tamayo-Rodríguez I; Martínez-Velilla N; Viguria-Alegria MC
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e348-e359. PubMed ID: 37487908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the
    Storti S; Spina M; Pesce EA; Salvi F; Merli M; Ruffini A; Cabras G; Chiappella A; Angelucci E; Fabbri A; Liberati AM; Tani M; Musuraca G; Molinari A; Petrilli MP; Palladino C; Ciancia R; Ferrario A; Gasbarrino C; Monaco F; Fraticelli V; De Vellis A; Merli F; Luminari S
    Haematologica; 2018 Aug; 103(8):1345-1350. PubMed ID: 29748444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
    Lin RJ; Owens CN; Drill E; Iannotta A; Oliveros M; Schick DL; Noy A; Gerecitano JF; Drullinsky PR; Caron PC; Kumar A; Matasar MJ; Moskowitz C; Korc-Grodzicki B; Zelenetz AD; Salles GA; Hamlin PA
    Haematologica; 2022 May; 107(5):1144-1152. PubMed ID: 34289656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
    Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
    PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.